Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Homa Porter

Urology Dallas, TX Medical Doctor

NPI 1073560058 CMS profile 3114

8230 Walnut Hill Ln, Suite 700, Dallas, TX 75231

Open in the dashboard

General payments

$6,040

248 records reported · program years 2019–2025

Research payments

$736

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,797,816 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Homa Porter of Dallas, TX is reported in the CMS Open Payments database as having received $6,040 across 248 general payments and $736 in research payments paid to them. Separately, studies naming them as principal investigator received $1,797,816 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 72nd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,383 65
2024 General $1,115 54
2023 General $872 41
2022 General $690 32
2021 General $397 21
2020 General $86 5
2019 General $497 30
2019 Research $736 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Homa Porter
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Homa Porter were reported at $2,383. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Homa Porter Urology median Middle half National median
2019 $497 $480 $147–$1,201 $163
2020 $86 $246 $87–$645 $114
2021 $397 $358 $111–$1,000 $132
2022 $690 $476 $143–$1,263 $149
2023 $872 $560 $168–$1,461 $160
2024 $1,115 $563 $170–$1,464 $164
2025 $2,383 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sumitomo Pharma America, Inc. $819 27 payments
  2. Olympus Corporation of the Americas $545 3 payments
  3. Dendreon Pharmaceuticals LLC $413 15 payments
  4. Janssen Biotech, Inc. $377 12 payments
  5. Merck Sharp & Dohme Corporation $349 13 payments
  6. AbbVie, Inc. $281 14 payments
  7. Astellas Pharma US Inc $263 14 payments
  8. Pfizer Inc. $228 11 payments
  9. Myovant Sciences Inc. $221 10 payments
  10. PROCEPT BioRobotics Corporation $213 7 payments
  11. Other $2,330 122 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,495 245 payments
  2. Travel and Lodging $545 3 payments
Products named General payments · program years 2019–2025
  1. ORGOVYX Hormone Therapy $666 27 payments
  2. iTIND System $656 8 payments
  3. XTANDI $427 22 payments
  4. PROVENGE $413 15 payments
  5. ORGOVYX Prostate Cancer $336 8 payments
  6. ERLEADA $326 10 payments
  7. KEYTRUDA $257 9 payments
  8. LYNPARZA $235 10 payments
  9. ORGOVYX Oncology $200 10 payments
  10. XIAFLEX $191 10 payments
  11. Other $3,170 162 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Allergan Inc. $736 6 payments

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

2,830

Median for Urology: 1,053

Drug cost

$2,501,945

Median for Urology: $101,464

Branded share of claims

35.4%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Erleada Apalutamide Brand 73 $1,036,333
Xtandi Enzalutamide Brand 49 $670,215
Orgovyx Relugolix Brand 193 $489,157
Myrbetriq Mirabegron Brand 265 $181,991
Gemtesa Vibegron Brand 82 $61,180
Tamsulosin Hcl Generic 746 $12,826
Mirabegron Er Mirabegron Brand 23 $10,355
Silodosin Generic 185 $8,673
Abiraterone Acetate Generic 28 $7,666
Dutasteride Generic 179 $5,523

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 111 billing codes

Paid by Medicare

$466,102

Of which drugs: $166,515

Medicare patients

1,043

Average age 76

Services billed

31,392

156 women, 887 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Ischemic heart disease 33%
Cancer 27%
Diabetes 26%
Chronic kidney disease 25%
Atrial fibrillation 23%
Depression 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 11 6,480 $131,175
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 29 231 $31,913
Injection, testosterone cypionate, 1 mg J1071 Office 11 15,500 $267
Injection, garamycin, gentamicin, up to 80 mg J1580 Office 30 55 $111

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ORGOVYX
$230 193 —
PROVENGE
$203 — —
Trelstar
$135 — —
XIAFLEX
$70 — —
LYNPARZA
$61 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

254 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record